Skip to main content

Advertisement

SpringerLink
Log in

Dementia in Parkinson’s Disease

  • Movement Disorders
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Dementia in Parkinson’s disease encompasses a spectrum relating to motor, psychiatric, and cognitive symptoms that are classified as either Dementia with Lewy Bodies (DLB) (initial cognitive symptoms) or Parkinson’s Disease Dementia (PDD) (initial motor signs preceding cognitive symptoms by at least a year). Anticholinergic and antipsychotic drugs have a high risk of adverse cognitive and/or motor effects, so their use should be minimized or avoided. Neuroleptic sensitivity is a severe psychomotor adverse reaction that is particularly associated with potent dopamine-blocking agents such as haloperidol. It occurs in up to 50% of individuals with PDD or DLB. Mild psychotic symptoms should first be addressed by reducing anticholinergic and/or dopaminergic agents, if possible. Patients with psychotic symptoms that threaten the safety of the patient or caregiver may benefit from treatment with quetiapine or, in refractory cases, clozapine. Cholinesterase inhibitors as a drug class have been shown to have beneficial effects on cognition in DLB and PDD, and may help to alleviate some psychiatric symptoms, such as apathy, anxiety, hallucinations, and delusions. Memantine may help to moderate cognitive symptoms in DLB and PDD, although current data suggest a more variable response, particularly in PDD. Parkinsonian motor signs that are accompanied by clinically significant cognitive impairment should be treated with carbidopa/levodopa only, as dopamine agonists and other antiparkinsonian medications generally carry a higher risk of provoking or exacerbating psychotic symptoms. Excessive daytime sleepiness and REM sleep behavior disorder are common associated features of PDD and DLB. Minimizing sedating medications during the day and promoting nocturnal sleep may help the daytime sleepiness; melatonin, clonazepam, gabapentin, and possibly memantine may be useful in treating REM sleep behavior disorder. Orthostatic hypotension can be managed with various nonpharmacologic interventions, and if needed, fludrocortisone and pyridostigmine. Midodrine should be used cautiously, if at all.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.

    Article  PubMed  CAS  Google Scholar 

  2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–92.

    Article  PubMed  Google Scholar 

  3. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.

    Article  PubMed  Google Scholar 

  4. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113–24.

    PubMed  CAS  Google Scholar 

  5. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.

    Article  PubMed  CAS  Google Scholar 

  6. Collerton D, Burn D, McKeith I, O’Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cog Disord. 2003;16:229–37.

    Article  Google Scholar 

  7. Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with Lewy bodies and Alzheimer’s disease. Mov Disord. 2006;21:337–42.

    Article  PubMed  Google Scholar 

  8. Bronnick K, Emre M, Lane R. Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:1064–8.

    Article  PubMed  Google Scholar 

  9. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;3:189–98.

    Article  Google Scholar 

  10. Kaufer DI, Williams SC, Braaten AJ, Gill K, Zimmerman S, Sloane PD. Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of three tests. J Am Med Dir Assoc. 2008;9:586–93.

    Article  PubMed  Google Scholar 

  11. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.

    Article  PubMed  Google Scholar 

  12. Nazem S, Siderowf AD, Duda JE, et al. Montreal Cognitive Assessment performance in patients with Parkinson’s disease with "normal" global cognition according to Mini-Mental State Examination score. J Am Geriatr Soc 2009;57:304–8.

    Article  PubMed  Google Scholar 

  13. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord. 2007;16:2314–24.

    Article  Google Scholar 

  14. McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–6.

    Article  PubMed  CAS  Google Scholar 

  15. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–18.

    Article  PubMed  CAS  Google Scholar 

  16. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708–12.

    Article  PubMed  CAS  Google Scholar 

  17. Leroi I, Brandt J, Reich SG, et al. Randomized trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry. 2004;19:1–8.

    Article  PubMed  Google Scholar 

  18. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934–9.

    Article  PubMed  CAS  Google Scholar 

  19. Edwards K, Royall D, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dem Geriatr Cog Disord. 2007;23:401–5.

    Article  CAS  Google Scholar 

  20. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613–8.

    Article  PubMed  CAS  Google Scholar 

  21. Emre M, Tsolaki M, Bonuccelli U, et al. on behalf of the 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;10:969–77.

    Article  Google Scholar 

  22. Tractenberg RE, Singer CM, Kaye JA. Symptoms of sleep disturbance in persons with Alzheimer’s disease and the normal elderly. J Sleep Res. 2005;14:177–85.

    Article  PubMed  Google Scholar 

  23. Boeve BF, Saper CB. REM sleep behavior disorder; a possible early marker for synucleinopathies. Neurology. 2006;66:796–7.

    Article  PubMed  Google Scholar 

  24. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in Sleep. Sleep. 2002;25:120–38.

    PubMed  Google Scholar 

  25. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9:293–308.

    PubMed  CAS  Google Scholar 

  26. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). American Academy of Sleep Medicine. J Clin Sleep Med. 2010;61:85–95.

    Google Scholar 

  27. Boeve B, Silber M, Ferman T. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med. 2003;4:281–4.

    Article  PubMed  Google Scholar 

  28. Larsson V, Aarsland D, et al. The effect of memantine on sleep behavior in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry. 2010;25:1030–8.

    Article  PubMed  Google Scholar 

  29. Hogl B, Saletu B, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25:905–9.

    PubMed  CAS  Google Scholar 

  30. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18:287–93.

    Article  PubMed  Google Scholar 

  31. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636–9.

    Article  PubMed  CAS  Google Scholar 

  32. Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65:1337–40.

    Article  PubMed  Google Scholar 

  33. Thaisetthawatkul P, Boeve B, Ferman T, et al. Autonomic dysfunction in Lewy body dementia. Neurology. 2004;62:1804–9.

    PubMed  CAS  Google Scholar 

  34. Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22:1543–9.

    Article  PubMed  Google Scholar 

  35. Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA 2010;304:2172–3.

    Article  PubMed  CAS  Google Scholar 

  36. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513–8.

    Article  PubMed  Google Scholar 

  37. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294–8.

    Article  PubMed  CAS  Google Scholar 

  38. Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847–51.

    Article  PubMed  CAS  Google Scholar 

  39. Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737–45.

    Article  PubMed  Google Scholar 

  40. Wolfgang JH. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci. 2010;289:69–73.

    Article  Google Scholar 

  41. Safarinejad MR, Taghva A, Shekarchi B, et al. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res. 2010; 22:325–35.

    Article  PubMed  CAS  Google Scholar 

  42. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37–40.

    PubMed  CAS  Google Scholar 

  43. Reijnders JS, Ehrt U, Weber WE, et al. A systemic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183–9.

    Article  PubMed  Google Scholar 

  44. Menza A, Dobkin R D, et al. Controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886–92.

    Article  PubMed  CAS  Google Scholar 

  45. Takahashi S, Mizukami K, et al. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9:56–61.

    Article  PubMed  Google Scholar 

  46. Friedman JH. Parkinson’s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16:553–60.

    Article  PubMed  Google Scholar 

  47. Gill SS, Bronskill SE, Normand SL. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775–86.

    PubMed  Google Scholar 

  48. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16–22.

    PubMed  Google Scholar 

  49. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20:958–63.

    Article  PubMed  Google Scholar 

  50. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months duration. Mov Disord. 2007;22:313–8.

    Article  PubMed  Google Scholar 

  51. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci. 2002;23:S89–90.

    Article  PubMed  Google Scholar 

  52. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–63.

    Article  Google Scholar 

  53. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999;353:2041–2.

    Article  Google Scholar 

  54. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord. 2006;21:2078–81.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of Interest: A. Kurtz: none; D. Kaufer: Consultant and member of Advisory Board for Accera, Forest Laboratories, Janssen, Medivation, Pfizer, Novartis, and Solvay Pharmaceuticals; payment for CME lectures and symposia for Forest Laboratories, Janssen, Pfizer, and Novartis.

Author information

Authors and Affiliations

  1. Department of Neurology, CB 7025, The University of North Carolina at Chapel Hill, 3129 Physician Office Building, Chapel Hill, NC, 27599, USA

    Avrom L. Kurtz MD & Daniel I. Kaufer MD

Authors
  1. Avrom L. Kurtz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel I. Kaufer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel I. Kaufer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurtz, A.L., Kaufer, D.I. Dementia in Parkinson’s Disease. Curr Treat Options Neurol 13, 242–254 (2011). https://doi.org/10.1007/s11940-011-0121-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-011-0121-1

Keywords

Search

Navigation